2Du F,Lv LJ,Fu Q,et al. T-614,a novel immunomodulator, at- tenuates joint inflammation and articular damage in eollagenin- dueed arthritis. Arthritis Res Therapy,2008,10(6) :R136.
3Hara M,Abe T,Sugawara S,et al. Efficacy and safety of igurati- rood compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol, 2007,17 ( 1 ) : 1-9.
7Aletaha D, Neogi T, Silman A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collab- orative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569.
8Smolen J S, Aletaha D, Bijlsma J W J, et al. Treating rheumatoid arthritis to target: recommendations of an inter national task force[J]. Ann Rheum Dis, 2010, 69(4) : 631.
9Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBI- TION study[J]. Ann Rheum Dis, 2010, 69(01): 88.
10Fleisehmann R, Kremer J, Cush J, et al. Placebo con- trolled trial of tofacitinib monotherapy in rheumatoid arthritis [J]. N EnglJ Med, 2012, 367(6): 495.
